The effect of minocycline on the symptoms of schizophrenia

The effect of minocycline on the symptoms of schizophrenia, a randomized double blind controlled clinical trial

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT201108223930N12

Enrollment

Registered

2011-11-08

Start date

2011-09-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

schizophrenia. Schizophrenia

Interventions

Intervention 1: minocycline 200 mg/day. Intervention 2: Placebo.

Treatment - Drugs

Placebo

minocycline 200 mg/day

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion Criteria: Age of 18-65 years; both genders; diagnosed Schizophrenia using DSM-IV diagnostic criteria; capable and willing to provide written informed consent by the patients and/or caregiver. Exclusion Criteria: Alcohol dependency; known or suspected pregnancy; women who are breastfeeding; and a known contraindication to minocycline treatment.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Positive and Negative Syndrome Scale for schizophrenia. Timepoint: (Pre-intervention), 2nd week, 4th week and 8th week. Method of measurement: Interview.	—

Countries

Iran (Islamic Republic of)

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026